Ritedose Launches Two New Single-Dose Syringe Products Amid National Drug Shortage: <em>Bupivacaine Hydrocholoride 0.25% (2.5 mg/mL) and Bupivacaine Hydrocholoride 0.5% (5 mg/mL)</em>
COLUMBIA, S.C. (November 17, 2022) – Ritedose, a 503B outsourcing facility located in South Carolina, just launched two new unit dose syringe products, Bupivacaine Hydrocholoride 0.25% (2.5 mg/mL) and Bupivacaine Hydrocholoride 0.5% (5 mg/mL). They are ready-to-use drug shortage solutions for hospital pharmacies across the country. Ritedose is a division
Recent Comments